NCT05428449

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029 Following Topical Single and Multiple Ascending Dose Administration

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 123 (actual)
• Sponsor: Suzhou Kintor Pharmaceutical Inc, · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

A randomized, double-blind, placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopecia(AGA) or acne

Conditions

• Androgenetic Alopecia
• Acne Vulgaris

Interventions

Type	Name	Description
DRUG	GT20029 Gel	Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
DRUG	GT20029 Gel Placebo	Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period

Timeline

• Start date: 2022-02-10
• Primary completion: 2022-10-27
• Completion: 2023-04-06
• First posted: 2022-06-23
• Last updated: 2023-08-14

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study